Hims & Hers Health (NYSE:HIMS) Hits New 52-Week Low – Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $22.95 and last traded at $23.4970, with a volume of 69296098 shares trading hands. The stock had previously closed at $24.40.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: New low‑price product could expand addressable market and drive new subscriptions — Hims said it will offer compounded semaglutide pills at a $49 introductory price (then $99/mo), potentially attracting price‑sensitive customers and increasing recurring revenue. Exclusive: Hims and Hers Health launches copy of Wegovy pill at $49
• Positive Sentiment: Non‑prescription services/diagnostics broaden product mix — Hims also announced plans to sell Grail’s Galleri multi‑cancer blood test through its platform, which diversifies revenue beyond prescriptions. Hims & Hers to sell Grail’s Galleri multi-cancer blood test
• Neutral Sentiment: Market reaction has been swift and mixed — initial bump to HIMS and pressure on large drugmakers showed investor sensitivity to oral GLP‑1 pricing and access; the longer‑term impact depends on regulatory outcomes and prescription uptake. Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers’ Stocks
• Negative Sentiment: Immediate legal threat from Novo Nordisk — Novo says Hims’ compounding amounts to “illegal mass compounding” and has said it will sue, creating near‑term litigation risk, potential injunctions and publicity headwinds. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
• Negative Sentiment: Regulatory and FDA attention — reports indicate the FDA chief may intervene or weigh in, and regulators could block distribution of compounded versions on safety/approval grounds, which would materially damage the initiative. Novo Nordisk stock climbs out of hole on FDA chief’s threat to block Hims and Hers pill
• Negative Sentiment: Short‑term share volatility and reputational/safety concerns — major outlets report selling after legal threats and safety accusations; even if Hims ultimately prevails, expect costly defense, potential sales disruption, and cautious prescribing. Hims & Hers falls 8% after Novo’s legal threat. Here’s the latest

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HIMS. Evercore ISI started coverage on shares of Hims & Hers Health in a research note on Monday, January 12th. They issued an “in-line” rating and a $33.00 price objective for the company. Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. BTIG Research decreased their price target on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a research note on Monday. Bank of America increased their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $42.62.

Hims & Hers Health Price Performance

The company has a market capitalization of $5.01 billion, a P/E ratio of 40.73, a PEG ratio of 4.02 and a beta of 2.43. The stock’s fifty day simple moving average is $33.30 and its 200-day simple moving average is $43.64. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has initiated a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,187 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer owned 70,232 shares of the company’s stock, valued at approximately $2,585,239.92. The trade was a 24.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 131,974 shares of company stock valued at $4,763,800. 13.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after acquiring an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $30,000. Janney Montgomery Scott LLC increased its position in shares of Hims & Hers Health by 15.1% during the second quarter. Janney Montgomery Scott LLC now owns 10,019 shares of the company’s stock valued at $499,000 after purchasing an additional 1,311 shares during the period. Truist Financial Corp raised its stake in shares of Hims & Hers Health by 20.7% in the second quarter. Truist Financial Corp now owns 9,643 shares of the company’s stock valued at $481,000 after purchasing an additional 1,656 shares in the last quarter. Finally, KLP Kapitalforvaltning AS lifted its position in Hims & Hers Health by 2.2% in the second quarter. KLP Kapitalforvaltning AS now owns 38,000 shares of the company’s stock worth $1,894,000 after purchasing an additional 800 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.